{"id":"NCT02436759","sponsor":"RVL Pharmaceuticals, Inc.","briefTitle":"Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis","officialTitle":"A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2016-11","completion":"2016-11","firstPosted":"2015-05-07","resultsPosted":"2020-10-20","lastUpdate":"2021-10-28"},"enrollment":140,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Blepharoptosis"],"interventions":[{"type":"DRUG","name":"RVL-1201","otherNames":["Oxymetazoline Hydrochloride Ophthalmic Solution 0.1%"]},{"type":"DRUG","name":"RVL-1201 Vehicle Placebo","otherNames":["RVL-1201 Ophthalmic Solution 0.1% Placebo"]}],"arms":[{"label":"RVL-1201","type":"EXPERIMENTAL"},{"label":"RVL-1201 Vehicle Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.","primaryOutcome":{"measure":"Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group","timeFrame":"Mean change from Baseline (Day 1, Hour 0) compared with Day 1, Hour 6 and Day 14, Hour 2","effectByArm":[{"arm":"RVL-1201","deltaMin":5.2,"sd":5.97},{"arm":"Vehicle Ophthalmic Solution","deltaMin":1.5,"sd":3.93}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":94},"commonTop":["Punctate keratitis","Vision blurred","Instillation site pain","Ocular hyperaemia","Upper respiratory tract infection"]}}